Literature DB >> 20369074

Therapeutic potential of histamine H3 receptor antagonists in dementias.

Paul L Chazot1.   

Abstract

Selective antagonism of centrally localized histamine H(3) receptors has been shown to enhance the release of a wide spectrum of important neurotransmitters including acetylcholine, gamma-aminobutyric acid, dopamine and noradrenalin, among others, which play fundamental roles in cognitive processes, in an output-dependent manner. The cognitive-enhancing effects of H(3) receptor antagonists across multiple cognitive domains in a wide number of preclinical cognition models also endow confidence in this therapeutic strategy for the treatment of Alzheimer's disease, attention deficit hyperactivity disorder and the cognitive deficits often expressed in schizophrenia. Recent positive clinical reports are beginning to reinforce this optimism. Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20369074     DOI: 10.1358/dnp.2010.23.2.1475899

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  7 in total

1.  Functional pharmacology of H1 histamine receptors expressed in mouse preoptic/anterior hypothalamic neurons.

Authors:  I V Tabarean
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 2.  Multiple Targeting Approaches on Histamine H3 Receptor Antagonists.

Authors:  Mohammad A Khanfar; Anna Affini; Kiril Lutsenko; Katarina Nikolic; Stefania Butini; Holger Stark
Journal:  Front Neurosci       Date:  2016-05-30       Impact factor: 4.677

3.  Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D2 and Histamine H3 Receptors: A PET Study in Healthy Rats.

Authors:  Nafiseh Ghazanfari; Aren van Waarde; Janine Doorduin; Jürgen W A Sijbesma; Maria Kominia; Martin Koelewijn; Khaled Attia; David Vállez-García; Antoon T M Willemsen; André Heeres; Rudi A J O Dierckx; Ton J Visser; Erik F J de Vries; Philip H Elsinga
Journal:  Mol Pharm       Date:  2022-06-22       Impact factor: 5.364

4.  Histamine H3 Inverse Agonist BF 2649 or Antagonist with Partial H4 Agonist Activity Clobenpropit Reduces Amyloid Beta Peptide-Induced Brain Pathology in Alzheimer's Disease.

Authors:  Ranjana Patnaik; Aruna Sharma; Stephen D Skaper; Dafin F Muresanu; José Vicente Lafuente; Rudy J Castellani; Ala Nozari; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

5.  Heteroreceptor Complexes Formed by Dopamine D1, Histamine H3, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimer's Disease.

Authors:  Mar Rodríguez-Ruiz; Estefanía Moreno; David Moreno-Delgado; Gemma Navarro; Josefa Mallol; Antonio Cortés; Carme Lluís; Enric I Canela; Vicent Casadó; Peter J McCormick; Rafael Franco
Journal:  Mol Neurobiol       Date:  2016-07-01       Impact factor: 5.590

6.  Effects of methimepip and JNJ-5207852 in Wistar rats exposed to an open-field with and without object and in Balb/c mice exposed to a radial-arm maze.

Authors:  Rushdie M A Abuhamdah; Ruan van Rensburg; Natasha L Lethbridge; Abdel Ennaceur; Paul L Chazot
Journal:  Front Syst Neurosci       Date:  2012-07-16

7.  Ligand autoradiographical quantification of histamine H3 receptor in human dementia with Lewy bodies.

Authors:  Natasha L Lethbridge; Paul L Chazot
Journal:  Pharmacol Res       Date:  2016-08-31       Impact factor: 7.658

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.